---
title: "T&K: Application for registration and listing permit of glucosamine sulfate capsules accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245408978.md"
description: "According to the Zhitong Finance APP, T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. recently received the \"Acceptance Notice\" for the application for the registration and marketing authorization of Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The National Medical Products Administration reviewed the application for the registration and marketing authorization of the above-mentioned drug and decided to accept it. Glucosamine Sulfate Capsules are suitable for primary and secondary osteoarthritis"
datetime: "2025-06-20T09:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245408978.md)
  - [en](https://longbridge.com/en/news/245408978.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245408978.md)
generator: "portal-rs"
---

# T&K: Application for registration and listing permit of glucosamine sulfate capsules accepted

According to the Zhitong Finance APP, T&K (301263.SZ) announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. recently received the "Acceptance Notice" for the domestic production drug registration application for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The National Medical Products Administration reviewed the drug registration application for the above-mentioned product and decided to accept it. Glucosamine Sulfate Capsules are suitable for primary and secondary osteoarthritis

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)

## Related News & Research

- [Hyrox founders reclaim majority stake in fitness-racing group with L Catterton-led investors](https://longbridge.com/en/news/298426349.md)
- [Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2](https://longbridge.com/en/news/298452346.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [Eiffage-led consortium wins civil works contract for Neomat CAM battery materials plant in Dunkirk area](https://longbridge.com/en/news/298482173.md)
- [EIQ: FDA setback delays heart failure solution, but strong finances and U.S. growth continue](https://longbridge.com/en/news/298376891.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**